ME00548B - Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti - Google Patents

Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti

Info

Publication number
ME00548B
ME00548B MEP-2008-679A MEP67908A ME00548B ME 00548 B ME00548 B ME 00548B ME P67908 A MEP67908 A ME P67908A ME 00548 B ME00548 B ME 00548B
Authority
ME
Montenegro
Prior art keywords
prevention
treatment
peripheral vascular
vascular diseases
inhibitors
Prior art date
Application number
MEP-2008-679A
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Publication of ME00548B publication Critical patent/ME00548B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Ovaj pronalazak se odnosi na upotrebu inhibitora IL-18 za pripremu leka za lečenje i/ili prevenciju perifernih vaskularnih bolesti. Ovaj pronalazak se dalje odnosi na upotrebu nekog inhibitora IL-18 za prevenciju amputacije ekstremiteta.
MEP-2008-679A 2002-03-22 2003-03-13 Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti ME00548B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22
PCT/EP2003/050061 WO2003080104A2 (en) 2002-03-22 2003-03-13 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Publications (1)

Publication Number Publication Date
ME00548B true ME00548B (me) 2011-10-10

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-679A ME00548B (me) 2002-03-22 2003-03-13 Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti

Country Status (28)

Country Link
US (2) US9592267B2 (me)
EP (1) EP1487541B1 (me)
JP (1) JP4885424B2 (me)
KR (1) KR20050004809A (me)
CN (1) CN100540058C (me)
AR (1) AR039103A1 (me)
AT (1) ATE414556T1 (me)
AU (1) AU2003219162B2 (me)
BR (1) BRPI0308663B8 (me)
CA (1) CA2478855C (me)
CY (1) CY1108748T1 (me)
DE (1) DE60324777D1 (me)
DK (1) DK1487541T3 (me)
EA (1) EA008495B1 (me)
ES (1) ES2314191T3 (me)
HK (1) HK1075422A1 (me)
HR (1) HRP20040758B1 (me)
IL (2) IL164211A0 (me)
ME (1) ME00548B (me)
MX (1) MXPA04009135A (me)
NO (1) NO336226B1 (me)
PL (1) PL207303B1 (me)
PT (1) PT1487541E (me)
RS (1) RS51755B (me)
SI (1) SI1487541T1 (me)
UA (1) UA80275C2 (me)
WO (1) WO2003080104A2 (me)
ZA (1) ZA200407022B (me)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
PT1487541E (pt) 2002-03-22 2008-12-10 Inst Nat Sante Rech Med Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
JP2007532697A (ja) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
RS52273B (en) 2005-06-10 2012-10-31 Ares Trading S.A. PROCESS FOR PURIFICATION OF IL-18 BINDING PROTEIN
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
CA2766354C (en) 2009-06-24 2019-08-13 Strategic Science & Technologies, Llc Topical compositions containing ibuprofen or sildenafil
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
EP2658554A4 (en) 2010-12-29 2015-01-07 Strategic Science & Tech Llc SYSTEMS AND METHOD FOR THE TREATMENT OF ALLERGIES AND OTHER INDICATIONS
ES2811515T3 (es) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Tratamiento de disfunción eréctil y otras indicaciones
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9895418B2 (en) * 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
BR112017017076A2 (pt) 2015-03-05 2018-04-10 Ab2 Bio Sa inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
RS50926B (sr) * 2000-05-05 2010-08-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
PT1487541E (pt) 2002-03-22 2008-12-10 Inst Nat Sante Rech Med Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas

Also Published As

Publication number Publication date
CN1655845A (zh) 2005-08-17
SI1487541T1 (sl) 2009-02-28
UA80275C2 (en) 2007-09-10
CY1108748T1 (el) 2014-04-09
JP2005520852A (ja) 2005-07-14
DK1487541T3 (da) 2009-01-19
AU2003219162A1 (en) 2003-10-08
HRP20040758A2 (en) 2005-02-28
HRP20040758B1 (hr) 2012-10-31
US9592267B2 (en) 2017-03-14
PT1487541E (pt) 2008-12-10
MXPA04009135A (es) 2004-12-07
IL164211A0 (en) 2005-12-18
EP1487541A2 (en) 2004-12-22
NO20044459L (no) 2004-10-20
US20100291028A1 (en) 2010-11-18
AR039103A1 (es) 2005-02-09
NO336226B1 (no) 2015-06-22
AU2003219162B2 (en) 2008-01-03
PL207303B1 (pl) 2010-11-30
BR0308663A (pt) 2005-01-25
BRPI0308663B1 (pt) 2019-07-16
CA2478855A1 (en) 2003-10-02
ZA200407022B (en) 2006-06-28
RS51755B (en) 2011-12-31
EA008495B1 (ru) 2007-06-29
US9566313B2 (en) 2017-02-14
KR20050004809A (ko) 2005-01-12
BRPI0308663B8 (pt) 2021-05-25
WO2003080104A3 (en) 2004-03-04
WO2003080104A2 (en) 2003-10-02
ATE414556T1 (de) 2008-12-15
US20060233799A1 (en) 2006-10-19
PL372398A1 (en) 2005-07-25
EP1487541B1 (en) 2008-11-19
HK1075422A1 (en) 2005-12-16
CA2478855C (en) 2013-12-17
JP4885424B2 (ja) 2012-02-29
RS81504A (en) 2006-12-15
EA200401240A1 (ru) 2005-02-24
IL164211A (en) 2011-07-31
CN100540058C (zh) 2009-09-16
ES2314191T3 (es) 2009-03-16
DE60324777D1 (de) 2009-01-02

Similar Documents

Publication Publication Date Title
ME00548B (me) Korišćenje inhibitora il-18 za liječenje i/ili prevenciju perifernih vaskularnih bolesti
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
ME00554B (me) KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
ECSP045429A (es) Combinacion de compuestos organicos
MEP90508A (en) New pharmaceutical composition
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
RS52945B (en) PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION
HUP0401501A2 (hu) Érrendszeri gyulladás kezelése vagy megelőzése szterin-felszívódást gátló anyagokat tartalmazó gyógyszerkészítmények alkalmazásával
ATE323490T1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
SE0200667D0 (sv) Novel use of cytokine inhibitors
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
MXPA05010416A (es) Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso.
ME00489B (me) NOVA SINERGIČKA KOMBINACIJA KOJA UKLJUČUJE ROFLUMILAST l FERMOTEROL
TNSN05154A1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
ECSP993018A (es) Nuevos inhibidores de proteasas, particularmente inhibidores de cisteina y serina proteasas